Ryan Mee, CEO of Fulcrum Metals, reviews FY23 and progress on the Gold Tailings Hub in Canada. Watch the video here.
Thanks Zoros, good summary, first thoughts, like the sound of it.
Halftime in the rugby - what a game! It's quite a statement from Janet, when she clearly knows her reply is in the public domain. Although she may have underestimated that the AVCT crew will be all over this. Are Novartis working on something with Avct for the future - time will tell. Back to the rugby.
Thanks Saint for the link - trying to watch the rugby at the same time!
Interesting observation on twitter - X - this evening. Would seem one of our "AVCT" crew has had a reply to his question from the Head Program Innovation Global Drug development at Novartis. In summary she likes what she's sees so far.
Thanks Muck and Timster. Coming from an untrained eye, are we potentially saying that 3996 could be the upgraded version of 6000 down the line? It could also attend to a greater variety of tumours than 6000. A nice problem to have but would you want to license out 3996 knowing it could replace 6000 eventually. Conscious at some point we will need funds from some type of deal to take 6000 through to market as 3996 has to be at least 3 years behind 6000. Or you look at other ways of funding and you state you are taking both through to market, thus creating a greater value to the platform and a potential buy out of the whole platform. Admit a lot of if and ands! Thoughts?
Thanks LLP
Out of interest and apologies for not googling, what sort of revenue is Point bringing in currently or in the future to obtain a 1.4billion buy out?
Given the news we have already received this week, what could we realistically obtain this coming Thursday, that we have not got yet. Thoughts?
GGP - Newmont maybe more professional (time will tell) but they are by no means bigger. Rio MCAP dwarfs Newmont.
Thanks Bamps, have a good weekend.
Bamps - if SD is that excited about Decka even though he has not seen the assays, there must be a possibility he has seen the cores or has received feedback on them. A possibility?
I remember the very early days of Hav, when they posted pictures of some cores, before they went to the labs. You could clearly see the "juicy" stuff! We can but hope for Decka.
Although many of us believe the SP should be much higher, the most important thing is that the narrative continues to get better, especially after a fantastic RNS this week. I don't think many of us believed on Monday morning what an update we were going to have this week. Of course lots more work to be done, there will be ups and downs. But at least we can end the week, knowing that Avacta continues to navigate the clinical trials with the utmost professionalism. Have weekend folks!
MM - thanks for your message. As someone who has held GGP dating back over 13 years, I must commend SD for all his work especially recently where I have been very impressed how he has navigated the extra 5%, governance and the recent funding facility of Wyloo. The only thing which frustrated me a little with his presentation was when he was asked why he hasn't bought share on the open market. Yes there will be many blackout periods, but you can't tell me there has not been one opportunity for him to purchase some shares on the market. That annoys me, he knows and explains how Hav is getting bigger and better yet he doesn't make a buy. I am a big fan of him, just that one thing stands out for me.
One final point, just as well they have Cadia firing on all cyclinders. $720 million in free cash flow, lovely!
Some interesting takeaways from Teller - AISC for the year up to $1633 from $1388. Free cashflow down to $9million from $103million. Although hedge losses of $75million doesn't help. All in all lower grade and lower gold sales. Time for Hav and a fresh start to get the giant back up and running.
Fantastic RNS, lots of hard work ahead, and time for the new CBO (once they have started) to draw up the contracts. Fingers crossed.
Hang on Sujood is Alan!
Alan to his EA this morning- "send for Sujood, we have a job for him"
Although not specifically mentioned under the use of funds apart from working capital. It is a great sign of confidence that Wyloo has in GGP. Does Wyloo believe that upcoming assays from GGP's other assets and JVs will be good? We can but dream!
As much as a $10,000 gold price would provide a bonkers margin for us, I would fear the world would be in a very sorry state of affairs. Am not sure I would want that. Just my opinion.